Is OPT with verteporfin still covered for CNV lesions that occupy >50% of the entire lesion?
Yes, OPT with verteporfin continues to be approved for patients with a diagnosis of neovascular AMD with predominately classic subfoveal (CNV) lesions (where the area of classic CNV occupies = 50% of the area of the entire lesion) at the initial visit as determined by a fluorescein angiogram. Note: This diagnosis must be determined by a fluorescein angiogram at the initial visit. Also, there are no requirements regarding visual acuity, lesion size, and number of re-treatments when treating predominantly classic lesion patients However, a fluorescein angiogram in subsequent, follow-up visits prior to treatment is required.
